The percentages of patients that were tested as positive by tumor markers were 85.7% (ProGRP, 18/21), 52.4% (NSE, 11/21) and 57.1% (CEA, 12/21), respectively, which demonstrated that the sequencing results of four types of pre-treatment samples were more reliable for cancer detection. The gene discussed is CEACAM5; the disease is cancer.